<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anencephaly</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anencephaly</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anencephaly</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tadanori Tomita, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hideki Ogiwara, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13323850"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anencephaly is characterized by an open defect in the calvaria and skin such that the cranial neural tube is exposed. It is a severe defect and is not compatible with survival. Nearly all liveborn infants with anencephaly die within the first few hours to days after birth. </p><p>The clinical features, diagnosis, and postnatal management of anencephaly are discussed in this topic review.</p><p>Anencephaly is one of the three major neural tube defects. The others are encephalocele and myelomeningocele, which are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>Encephalocele is a herniation of the brain and/or meninges through a defect in the skull (cranium bifidum) that is "closed" or covered with skin. (See  <a class="medical medical_review" href="/z/d/html/6171.html" rel="external">"Primary (congenital) encephalocele"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myelomeningocele is characterized by a cleft in the vertebral column, with a corresponding defect in the skin so that the meninges and spinal cord are exposed. (See  <a class="medical medical_review" href="/z/d/html/6170.html" rel="external">"Myelomeningocele (spina bifida): Anatomy, clinical manifestations, and complications"</a> and  <a class="medical medical_review" href="/z/d/html/6219.html" rel="external">"Myelomeningocele (spina bifida): Management and outcome"</a>.)</p><p></p><p class="headingAnchor" id="H13324094"><span class="h1">EMBRYOLOGY</span><span class="headingEndMark"> — </span>The central nervous system appears as a plate of thickened ectoderm called the neural plate at the beginning of the third week of embryonic life. The lateral edges of the neural plate become elevated to form the neural folds and fuse to form the neural tube; the fusion begins in the cervical region and proceeds in both the rostral and caudal directions  (<a class="graphic graphic_figure graphicRef81711" href="/z/d/graphic/81711.html" rel="external">figure 1</a>). The rostral neuropore closes on the 25<sup>th</sup> day after conception, and the caudal neuropore closes two days later [<a href="#rid1">1</a>]. Neural tube defects (NTDs) result from failure of the neural tube closure between 25 and 27 days after conception. The embryology of the neural tube is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/14405.html" rel="external">"Closed spinal dysraphism: Pathogenesis and types", section on 'Normal cord development in humans'</a>.)</p><p>Anencephaly is a severe defect of development of the neuraxis, in which the developing forebrain and variable amounts of the brainstem are exposed in utero and fail to develop or are destroyed [<a href="#rid2">2,3</a>]. The generally accepted pathologic mechanism of anencephaly is the acrania-exencephaly-anencephaly sequence [<a href="#rid4">4</a>]. Failure of the rostral neuropore to close around postovulatory day 25 causes absence of skull, meninges, and muscles (acrania) [<a href="#rid5">5</a>]. Subsequently, the fetal brain protrudes outward and is exposed to the amniotic fluid (exencephaly). This process causes destruction and degeneration of the brain (anencephaly).</p><p>The craniofacial abnormalities in anencephaly are caused by abnormal neural induction from prosencephalic and mesencephalic neural crest tissue [<a href="#rid6">6</a>]. This mechanism is also seen in other anomalies of craniofacial development such as holoprosencephaly.</p><p>Craniorachischisis totalis is a related NTD in which anencephaly is accompanied by a contiguous open defect of the spine (spina bifida totalis). It is an extreme example of defective closure of the neural tube during early embryogenesis, around 20 to 22 days gestation [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H13324782"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>According to data from birth certificates reported to the National Center for Health Statistics, the prevalence of anencephaly in the United States in 2001 was 9.40 per 100,000 live births [<a href="#rid9">9</a>]. During 1999 to 2004, 2116 cases of anencephaly were reported in the United States [<a href="#rid10">10</a>]. Hispanic infants had the highest prevalence. The malformation is more common in girls than boys, in White than Black infants, and in mothers at the younger and older extremes of age [<a href="#rid11">11</a>]. The rate of anencephaly in live births underestimates the actual rate of occurrence because of unknown numbers of spontaneous abortion or pregnancy termination of affected fetuses.</p><p>The birth prevalence of anencephaly decreased 20 percent between the 1999 to 2000 period and the 2003 to 2004 survey periods [<a href="#rid10">10</a>]. This decline is thought to be due to mandatory fortification of foods with <a class="drug drug_pediatric" data-topicid="13322" href="/z/d/drug information/13322.html" rel="external">folic acid</a>, which began in January 1998.</p><p>There is considerable variation in the rates of anencephaly and other neural tube defects worldwide, with particularly high prevalence in Ireland and the British Islands as compared with continental Europe [<a href="#rid12">12</a>]. Rates in Asia and Africa tend to be lower, although there are pockets of higher prevalence in the northern provinces of China and in India, which are not easily explained by geographic or ethnic gradients [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H13324789"><span class="h1">RECURRENCE RISK</span><span class="headingEndMark"> — </span>The risk of recurrence for neural tube defects (NTDs) (spina bifida or anencephaly) is approximately 2 to 4 percent when there is one affected sibling [<a href="#rid14">14-18</a>]. With two affected siblings, the risk is approximately 10 percent [<a href="#rid19">19</a>]. The risk of recurrence appears to be higher in countries such as Ireland where the prevalence of NTDs is high [<a href="#rid20">20</a>]. This familial clustering is due to genetic factors, environmental influences, or a combination of the two [<a href="#rid21">21</a>].</p><p>The environmental influences that contribute to anencephaly risk are similar to those of other NTDs. (See <a class="local">'Prevention'</a> below.)</p><p class="headingAnchor" id="H13324796"><span class="h1">PRENATAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Prenatal diagnosis of anencephaly is made with ultrasonography, which shows absence of brain and calvaria superior to the orbits on coronal views of the fetal head  (<a class="graphic graphic_diagnosticimage graphicRef50131 graphicRef71153" href="/z/d/graphic/50131.html" rel="external">image 1A-B</a>). The sonographic diagnosis of this condition is highly accurate and should be readily apparent on routine second- or third-trimester ultrasound examination. Another sonographic feature is polyhydramnios, which develops in up to 50 percent of the cases during the second and third trimester due to decreased fetal swallowing. Anencephalies are classified into several phenotypic types based on the ultrasound findings [<a href="#rid22">22</a>]. Prenatal ultrasound diagnosis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6831.html" rel="external">"Neural tube defects: Prenatal sonographic diagnosis", section on 'Exencephaly-anencephaly sequence'</a>.)</p><p>Prenatal diagnosis is usually followed by discussion of reproductive options (termination or continuation of the pregnancy). (See  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management", section on 'Anencephaly'</a>.)</p><p class="headingAnchor" id="H13324803"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>In the most common type of anencephaly, the forebrain and variable amounts of upper brainstem are involved [<a href="#rid11">11</a>]. Exposure in utero results in destruction of neural tissue, which appears as a hemorrhagic, fibrotic, nonfunctioning mass  (<a class="graphic graphic_picture graphicRef70158" href="/z/d/graphic/70158.html" rel="external">picture 1</a>). Major portions of the central nervous system are absent or malformed. The hypothalamus is typically missing. The cerebellum, brainstem, optic nerves, and spinal cord may be malformed. Underdevelopment or absence of the pituitary, leading to adrenal hypoplasia, is always present [<a href="#rid23">23</a>].</p><p>Large portions of the cranium are absent in this disorder. The frontal, parietal, and portions of the occipital bones are most often affected. The absent cranial vault results in the characteristic appearance of bulging eyes and absent neck. The defect in the skull sometimes extends through the level of the foramen magnum and involves the cervical spine. This abnormality is known as holoacrania [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H13324810"><span class="h2">Associated malformations</span><span class="headingEndMark"> — </span>Other congenital malformations frequently accompany anencephaly. In a registry of 456 affected stillborn and liveborn infants in British Columbia, Canada, additional malformations, including cleft lip and/or palate or omphalocele, occurred in 12.7 percent [<a href="#rid24">24</a>]. Craniofacial and ocular anomalies often occur. Cardiac, pulmonary, renal, and skeletal malformations may be associated. Aganglionosis of the intestine is a frequent finding [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H13324817"><span class="h2">Neurologic function</span><span class="headingEndMark"> — </span>Neonates with anencephaly typically have brainstem function, with spontaneous breathing and often with suck, root, and gag responses. However, they are permanently unconscious. Without intensive care, the majority of them die within the first few days after birth [<a href="#rid11">11</a>]. Survival past two weeks has not been reported.</p><p class="headingAnchor" id="H13324824"><span class="h1">POSTNATAL MANAGEMENT</span><span class="headingEndMark"> — </span>Nearly all liveborn infants die shortly after birth. There are no neurosurgical management options. Given this poor prognosis, most pregnancies are terminated or induced shortly after diagnosis. (See  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management", section on 'Anencephaly'</a>.)</p><p>Management of liveborn anencephalic newborns focuses on comfort measures and providing support for the family. (See  <a class="medical medical_review" href="/z/d/html/6252.html" rel="external">"Pediatric palliative care", section on 'End-of-life care'</a>.)</p><p>Some affected families may ask whether organ donation is an option. A diagnosis of anencephaly does not preclude consideration for organ donation, particularly donation after circulatory determination of death (DCDD) [<a href="#rid26">26</a>]. However, in many cases, organ donation (either using brain death or DCDD criteria) is not feasible for anencephalic infants because by the time brain or circulatory death occurs, most organs are damaged to an extent that they are no longer suitable for transplantation [<a href="#rid27">27</a>]. Families who wish to pursue organ donation should be informed of this possibility. Clinicians caring for anencephalic newborns should consult with an organ procurement organization to facilitate these discussions. (See  <a class="medical medical_review" href="/z/d/html/1663.html" rel="external">"Assessment of the pediatric patient for potential organ donation"</a>.)</p><p class="headingAnchor" id="H13324831"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Several lines of evidence suggest a link between <a class="drug drug_pediatric" data-topicid="13322" href="/z/d/drug information/13322.html" rel="external">folic acid</a> deficiency and the development of neural tube defects (NTDs) including anencephaly [<a href="#rid28">28</a>]. Risk factors for NTDs include dietary deficiency of folic acid; administration of <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproate</a> or folic acid antagonists such as <a class="drug drug_pediatric" data-topicid="12865" href="/z/d/drug information/12865.html" rel="external">trimethoprim</a>, <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a>, <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, and <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>; and genetic polymorphisms in genes encoding folate-dependent enzymes. Other contributors to NTD risk that are probably not related to folate metabolism include maternal diabetes mellitus with poor glycemic control during the first trimester, hyperthermia, and some genetic syndromes. (See  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management", section on 'Risk factors'</a>.)</p><p>Periconceptional <a class="drug drug_pediatric" data-topicid="13322" href="/z/d/drug information/13322.html" rel="external">folic acid</a> supplementation is recommended for all women who are pregnant or who may become pregnant. Higher doses of folic acid supplements are usually recommended for women who are taking antiseizure medications or who have had a previous pregnancy affected by an NTD. Randomized trials have consistently shown that folic acid supplementation reduces the incidence of NTDs. This issue is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p class="headingAnchor" id="H3719838510"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118927.html" rel="external">"Society guideline links: Congenital malformations of the central nervous system"</a>.)</p><p class="headingAnchor" id="H13325264"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Anencephaly is a severe defect of development of the neuraxis, in which the developing forebrain and variable amounts of the brainstem are exposed in utero and destroyed or fail to develop  (<a class="graphic graphic_picture graphicRef70158" href="/z/d/graphic/70158.html" rel="external">picture 1</a>). Neonates with anencephaly typically have brainstem function but are permanently unconscious. It is a severe defect and is not compatible with survival. Nearly all liveborn infants with anencephaly die within the first few hours to days after birth. (See <a class="local">'Neurologic function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Most isolated open neural tube defects (NTDs), including anencephaly, appear to be caused by folate deficiency, likely in combination with genetic or other environmental risk factors. (See  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal diagnosis</strong> – Prenatal diagnosis of anencephaly is made with ultrasonography, which shows absence of brain and calvaria superior to the orbits on coronal views of the fetal head  (<a class="graphic graphic_diagnosticimage graphicRef50131 graphicRef71153" href="/z/d/graphic/50131.html" rel="external">image 1A-B</a>). The sonographic diagnosis of this condition is highly accurate and should be readily apparent on routine second- or third-trimester ultrasound examination. Prenatal diagnosis is usually followed by discussion of reproductive options (termination or continuation of the pregnancy). Prenatal screening and diagnosis of NTDs are reviewed in greater detail separately. (See <a class="local">'Prenatal diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postnatal management</strong> – Nearly all liveborn infants with anencephaly die shortly after birth. There are no neurosurgical management options. Given the poor prognosis, most pregnancies are terminated or induced shortly after diagnosis. Management of liveborn anencephalic newborns focuses on comfort measures and providing support for the family. (See <a class="local">'Postnatal management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – <a class="drug drug_pediatric" data-topicid="13322" href="/z/d/drug information/13322.html" rel="external">Folic acid</a> supplementation is an effective intervention to decrease the occurrence of NTDs and is recommended for all pregnant individuals, as discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Sadler TW. Langman's Medical Embryology, Lippincott Williams &amp; Wilkins, Philadelphia 1990. p.352.</li><li class="breakAll">Lemire RJ, Beckwith JB, Warkuny J. Anencephaly, Raven Press, New York 1978.</li><li><a class="nounderline abstract_t">Stone DH. The declining prevalence of anencephalus and spina bifida: its nature, causes and implications. Dev Med Child Neurol 1987; 29:541.</a></li><li><a class="nounderline abstract_t">Wilkins-Haug L, Freedman W. Progression of exencephaly to anencephaly in the human fetus--an ultrasound perspective. Prenat Diagn 1991; 11:227.</a></li><li class="breakAll">O'Rahilly M, Muller F. Human Embryology &amp; Teratology, Wiley-Liss, Inc, New York 1992. p.253.</li><li><a class="nounderline abstract_t">Sarnat HB, Flores-Sarnat L. Embryology of the neural crest: its inductive role in the neurocutaneous syndromes. J Child Neurol 2005; 20:637.</a></li><li><a class="nounderline abstract_t">Coskun A, Kiran G, Ozdemir O. Craniorachischisis totalis: a case report and review of the literature. Fetal Diagn Ther 2009; 25:21.</a></li><li><a class="nounderline abstract_t">Naveen N, Murlimanju, Vishal K, Maligi A. Craniorachischisis totalis. J Neurosci Rural Pract 2010; 1:54.</a></li><li><a class="nounderline abstract_t">Mathews TJ, Honein MA, Erickson JD. Spina bifida and anencephaly prevalence--United States, 1991-2001. MMWR Recomm Rep 2002; 51:9.</a></li><li><a class="nounderline abstract_t">Boulet SL, Yang Q, Mai C, et al. Trends in the postfortification prevalence of spina bifida and anencephaly in the United States. Birth Defects Res A Clin Mol Teratol 2008; 82:527.</a></li><li class="breakAll">Volpe JJ. Intracranial hemorrhage: Neural tube formation and prosencephalic development. In: Neurology of the Newborn, 4th, WB Saunders, Philadelphia 2001. p.3.</li><li><a class="nounderline abstract_t">Frey L, Hauser WA. Epidemiology of neural tube defects. Epilepsia 2003; 44 Suppl 3:4.</a></li><li><a class="nounderline abstract_t">Li Z, Ren A, Zhang L, et al. Extremely high prevalence of neural tube defects in a 4-county area in Shanxi Province, China. Birth Defects Res A Clin Mol Teratol 2006; 76:237.</a></li><li><a class="nounderline abstract_t">Cowchock S, Ainbender E, Prescott G, et al. The recurrence risk for neural tube defects in the United States: a collaborative study. Am J Med Genet 1980; 5:309.</a></li><li><a class="nounderline abstract_t">Toriello HV, Higgins JV. Occurrence of neural tube defects among first-, second-, and third-degree relatives of probands: results of a United States study. Am J Med Genet 1983; 15:601.</a></li><li><a class="nounderline abstract_t">Seller MJ. Recurrence risks for neural tube defects in a genetic counseling clinic population. J Med Genet 1981; 18:245.</a></li><li><a class="nounderline abstract_t">Czeizel A, Métneki J. Recurrence risk after neural tube defects in a genetic counselling clinic. J Med Genet 1984; 21:413.</a></li><li><a class="nounderline abstract_t">Koch M, Fuhrmann W. Sibs of probands with neural tube defects--a study in the Federal Republic of Germany. Hum Genet 1985; 70:74.</a></li><li class="breakAll">Nussbaum R, McInnes RR, Willard HF. Genetics of disorders with complex inheritance. In: Thompson &amp; Thompson Genetics in Medicine, 6, WB Saunders, Philadelphia 2001. p.289.</li><li><a class="nounderline abstract_t">MacCarthy PA, Dalrymple IJ, Duignan NM, et al. Recurrence rates of neural tube defects in Dublin maternity hospitals. Ir Med J 1983; 76:78.</a></li><li><a class="nounderline abstract_t">Copp AJ, Greene ND. Genetics and development of neural tube defects. J Pathol 2010; 220:217.</a></li><li><a class="nounderline abstract_t">Wertaschnigg D, Reddy M, Ramkrishna J, et al. Ultrasound Appearances of the Acrania-Anencephaly Sequence at 10 to 14 Weeks' Gestation. J Ultrasound Med 2020; 39:1695.</a></li><li><a class="nounderline abstract_t">Mazzitelli N, Vauthay L, Grandi C, et al. Reviewing old concepts at the start of a new millenium: growth restriction, adrenal hypoplasia, and thymomegaly in human anencephaly. Teratology 2002; 66:105.</a></li><li><a class="nounderline abstract_t">Sadovnick AD, Baird PA. Congenital malformations associated with anencephaly in liveborn and stillborn infants. Teratology 1985; 32:355.</a></li><li><a class="nounderline abstract_t">Mathew A. Anencephaly-associated aganglionosis. Am J Med Genet 1998; 80:518.</a></li><li><a class="nounderline abstract_t">Weiss MJ, Hornby L, Rochwerg B, et al. Canadian Guidelines for Controlled Pediatric Donation After Circulatory Determination of Death-Summary Report. Pediatr Crit Care Med 2017; 18:1035.</a></li><li><a class="nounderline abstract_t">Peabody JL, Emery JR, Ashwal S. Experience with anencephalic infants as prospective organ donors. N Engl J Med 1989; 321:344.</a></li><li><a class="nounderline abstract_t">Kancherla V. Countries with an immediate potential for primary prevention of spina bifida and anencephaly: Mandatory fortification of wheat flour with folic acid. Birth Defects Res 2018; 110:956.</a></li></ol></div><div id="topicVersionRevision">Topic 16869 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sadler TW. Langman's Medical Embryology, Lippincott Williams &amp; Wilkins, Philadelphia 1990. p.352.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lemire RJ, Beckwith JB, Warkuny J. Anencephaly, Raven Press, New York 1978.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3315792" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The declining prevalence of anencephalus and spina bifida: its nature, causes and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1896409" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Progression of exencephaly to anencephaly in the human fetus--an ultrasound perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1896409" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Progression of exencephaly to anencephaly in the human fetus--an ultrasound perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16225807" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Embryology of the neural crest: its inductive role in the neurocutaneous syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129707" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Craniorachischisis totalis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799625" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Craniorachischisis totalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353510" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Spina bifida and anencephaly prevalence--United States, 1991-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18481813" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Trends in the postfortification prevalence of spina bifida and anencephaly in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18481813" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Trends in the postfortification prevalence of spina bifida and anencephaly in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12790881" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiology of neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575897" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Extremely high prevalence of neural tube defects in a 4-county area in Shanxi Province, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7405962" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The recurrence risk for neural tube defects in the United States: a collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614048" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Occurrence of neural tube defects among first-, second-, and third-degree relatives of probands: results of a United States study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7277415" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrence risks for neural tube defects in a genetic counseling clinic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6512828" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Recurrence risk after neural tube defects in a genetic counselling clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873392" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sibs of probands with neural tube defects--a study in the Federal Republic of Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873392" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sibs of probands with neural tube defects--a study in the Federal Republic of Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6341309" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recurrence rates of neural tube defects in Dublin maternity hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19918803" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Genetics and development of neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32154944" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ultrasound Appearances of the Acrania-Anencephaly Sequence at 10 to 14 Weeks' Gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12210471" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reviewing old concepts at the start of a new millenium: growth restriction, adrenal hypoplasia, and thymomegaly in human anencephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4082066" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Congenital malformations associated with anencephaly in liveborn and stillborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9880220" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Anencephaly-associated aganglionosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28925929" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Canadian Guidelines for Controlled Pediatric Donation After Circulatory Determination of Death-Summary Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2664521" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Experience with anencephalic infants as prospective organ donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29532629" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Countries with an immediate potential for primary prevention of spina bifida and anencephaly: Mandatory fortification of wheat flour with folic acid.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
